目的 探討注射用纖溶酶聯(lián)合阿托伐他汀鈣片治療短暫性腦缺血發(fā)作的臨床效果。方法 選取2015年1月—2016年7月樂(lè)山市中醫(yī)醫(yī)院收治的短暫性腦缺血患者90例，按隨機(jī)數(shù)字表法將患者分為對(duì)照組和治療組，每組各45例。對(duì)照組靜脈滴注注射用纖溶酶，首次劑量100 U加入到5%葡萄糖注射液250 mL，再次劑量加倍，輸注時(shí)間60 min，1次/d。治療組在對(duì)照組基礎(chǔ)上睡前口服阿托伐他汀鈣片，2片/次，1次/d。兩組均連續(xù)治療6個(gè)月。觀察兩組的臨床療效，比較兩組的血液流變學(xué)指標(biāo)和血脂水平。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為75.6%、91.1%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組纖維蛋白原（FIB）、全血低切黏度（LBV）、全血高切黏度（HBV）、血漿黏度（SV）和血小板聚集率（PAR）明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組三酰甘油（TG）、總膽固醇（TC）和低密度脂蛋白膽固醇（LDL-C）水平顯著降低，而高密度脂蛋白膽固醇（HDL-C）水平顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。結(jié)論 注射用纖溶酶聯(lián)合阿托伐他汀鈣片治療短暫性腦缺血發(fā)作具有較好的臨床療效，能改善血液流變學(xué)指標(biāo)和血脂水平，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the effect of Fibrinogenase for injection combined with Atorvastatin Calcium Tablets in treatment of transient ischemic attack. Methods Patients (90 cases) with transient ischemic attack in Leshan Hospital of Traditional Chinese Medicine from January 2015 to July 2016 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were iv administered with Fibrinogenase for injection, first dose 100 U added into 5% glucose solution 250 mL, then double dose, infusion time for 60 min, once daily. Patients in the treatment group were po administered with Atorvastatin Calcium Tablets on the basis of the control group before going to bed, 2 tablets/time, once daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and blood rheology indexes and blood lipid levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 75.6% and 91.1%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of FIB, LBV, HBV, SV, and PAR in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of TG, TC, and LDL-C in two groups were significantly decreased, but the levels of HDL-C in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Fibrinogenase for injection combined with Atorvastatin Calcium Tablets has clinical curative effect in treatment of transient ischemic attack, can improve blood rheology indexes and blood lipid level, with good safety, which has a certain clinical application value.